CD274 and cancer: Hereto, accumulating combination strategies are developed to improve α-PD-1/PD-L1 efficacy and alleviate treatment resistance by enhancing immunogenic cancer cell death, promoting antigen presentation, and rescuing other dysfunctional effectors [54–57].